| Literature DB >> 33419766 |
Ting Lu1, Li Chen1, Anthony G Mansour1, Melissa J Yu1, Noah Brooks1, Kun-Yu Teng1, Zhenlong Li1, Jianying Zhang2, Tasha Barr1, Jianhua Yu1,3,4,5, Michael A Caligiuri6,3,4,5.
Abstract
The E3 ubiquitin ligase Cbl-b has been characterized as an intracellular checkpoint in T cells; however, the function of Cbl-b in primary human NK cells, an innate immune anti-tumor effector cell, is not well defined. In this study, we show that the expression of Cbl-b is significantly upregulated in primary human NK cells activated by IL-15, IL-2, and the human NK cell-sensitive tumor cell line K562 that lacks MHC class I expression. Pretreatment with JAK or AKT inhibitors prior to IL-15 stimulation reversed Cbl-b upregulation. Downregulation of Cbl-b resulted in significant increases in granzyme B and perforin expression, IFN-γ production, and cytotoxic activity against tumor cells. Collectively, we demonstrate upregulation of Cbl-b and its inhibitory effects in IL-15/IL-2/K562-activated human NK cells, suggesting that Cbl-b plays a negative feedback role in human NK cells.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33419766 PMCID: PMC8184061 DOI: 10.4049/jimmunol.2000177
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.426